Advertise with us
Life Sciences Group

International Journal of Veterinary Science and Research



Abstract Open Access
Case Report PTZAID: IJVSR-1-103

Increased Survival after Treatment of Canine Hemangiosarcoma with Fenofibrate

Johanna K Ecke, Luis Del Valle, Amanda Parker Struckhoff, Piotr Waligorski, Krzysztof Reiss and Francesca Peruzzi*

Hemangiosarcoma (HSA) is a common and highly metastatic tumor that affects predominantly large-breed dogs. The median survival time for dogs diagnosed with splenic HSA without adjuvant chemotherapy after surgery is 86 days. Fenofibrate is an FDA-approved drug commonly utilized to treat high cholesterol and high triglyceride levels in humans. However, fenofibrate has also been shown to possess anti-proliferative and anti-metastatic properties against several aggressive and highly metastatic tumors in vitro and in small animal models.We report a case of a 6.5-year-old dog diagnosed with a splenic hemangiosarcoma and treated solely with micronized fenofibrate, administered orally once a day following splenectomy. The dog survived for over 26 months (804 days) after initial diagnosis without signs of adverse effects due to fenofibrate treatment

Published on: Oct 16, 2015 Pages: 8-10

Full Text PDF Full Text HTML DOI: 10.17352/ijvsr.000003


Peertechz @Social

Peertechz Tweets

Case Reports

Pinterest on IJVSR